IP Library › Granted Patent US 12,331,102
Granted Patent B2
US 12,331,102 · App. 15/909,314 · Granted Jun 17, 2025

APOA-1 fusion polypeptides and related compositions

Inventors: Martha S. Hayden-Ledbetter (Shoreline, WA); Jeffrey A. Ledbetter (Shoreline, WA)
Assignee: Theripion, Inc.
C07K14/775C12N9/18C12N9/22C12N15/62C12Y301/01002C12Y301/01047C12Y301/08001C07K2319/30C12Y301/27005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,331,102
App. No.
15/909,314
Granted
Jun 17, 2025
Kind
B2
Abstract

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

Claims (69)

1. A fusion polypeptide comprising, from an amino-terminal position to a carboxyl-terminal position, ApoA1-L1-D, wherein:

ApoA1 is a first polypeptide segment comprising the amino acid sequence shown in residues 19-267 or 25-267 of SEQ ID NO:2, wherein said first polypeptide segment has cholesterol efflux activity;

L1 is a first polypeptide linker consisting of 16 to 36 amino acid residues; and

D is an immunoglobulin Fc region,

wherein the fusion polypeptide has increased cholesterol efflux activity as compared to the ApoA1-L1-D fusion polypeptide in which L1 is a two amino acid linker or is absent, and

wherein the fusion polypeptide comprises the amino acid sequence shown in

(i) residues 19-525, 19-524, 25-525, or 25-524 of SEQ ID NO:2,

(ii) residues 19-525, 19-524, 25-525, or 25-524 of SEQ ID NO:13,

(iii) residues 19-515, 19-514, 25-515, or 25-514 of SEQ ID NO:22,

(iv) residues 19-520, 19-519, 25-520, or 25-519 of SEQ ID NO:26, or

(v) residues 19-535, 19-534, 25-535, or 25-534 of SEQ ID NO:24.

2. The fusion polypeptide of claim 1 , further comprising a second polypeptide segment located carboxyl-terminal to the immunoglobulin Fc region, wherein the second polypeptide segment is selected from the group consisting of an RNase and a paraoxonase,

wherein the fusion polypeptide comprises, from an amino-terminal position to a carboxyl-terminal position, ApoA1-L1-D-L2-P, wherein ApoA1, L1, and D are as defined in claim 1 , L2 is a second polypeptide linker, wherein L2 is optionally present, and P is the second polypeptide segment.

3. The fusion polypeptide of claim 2 , wherein the second polypeptide segment is the RNase.

4. The fusion polypeptide of claim 3 , wherein the RNase has at least 95% identity with amino acid residues 544-675 or 548-675 of SEQ ID NO:4.

5. The fusion polypeptide of claim 4 , wherein the RNase has the amino acid sequence shown in residues 544-675 or 548-675 of SEQ ID NO:4.

6. The fusion polypeptide of claim 3 , wherein the fusion polypeptide comprises the amino acid sequence shown in

(i) residues 19-675 or 25-675 of SEQ ID NO:4,

(ii) residues 19-675 or 25-675 of SEQ ID NO:14,

(iii) residues 19-671 or 25-671 of SEQ ID NO:58, or

(iv) residues 19-671 or 25-671 of SEQ ID NO:59.

7. The fusion polypeptide of claim 2 , wherein the second polypeptide segment is the paraoxonase.

8. The fusion polypeptide of claim 7 , wherein the paraoxonase has at least 95% identity with amino acid residues 16-355 of SEQ ID NO:12, amino acid residues 16-355 of SEQ ID NO:42, or amino acid residues 16-355 of SEQ ID NO:44.

9. The fusion polypeptide of claim 8 , wherein the paraoxonase has the amino acid sequence shown in residues 16-355 of SEQ ID NO:12, residues 16-355 of SEQ ID NO: 42, or residues 16-355 of SEQ ID NO:44.

10. The fusion polypeptide of claim 7 , wherein the fusion polypeptide comprises the amino acid sequence shown in

(i) residues 19-883 or 25-883 of SEQ ID NO:28,

(ii) residues 19-873 or 25-873 of SEQ ID NO:38,

(iii) residues 19-883 or 25-883 of SEQ ID NO:46, or

(iv) residues 19-883 or 25-883 of SEQ ID NO:48.

11. A dimeric protein comprising a first fusion polypeptide and a second fusion polypeptide, wherein each of said first and second fusion polypeptides is a fusion polypeptide as defined in claim 1 .

12. A composition comprising:

the dimeric protein of claim 11 ; and

a pharmaceutically acceptable carrier.

13. A dimeric protein comprising a first fusion polypeptide and a second fusion polypeptide, wherein each of said first and second fusion polypeptides is a fusion polypeptide as defined in claim 2 .

14. A composition comprising:

the dimeric protein of claim 13 ; and

a pharmaceutically acceptable carrier.

15. A dimeric protein comprising a first fusion polypeptide and a second fusion polypeptide, wherein each of said first and second fusion polypeptides is a fusion polypeptide as defined in claim 3 .

16. A composition comprising:

the dimeric protein of claim 15 ; and

a pharmaceutically acceptable carrier.

17. A dimeric protein comprising a first fusion polypeptide and a second fusion polypeptide, wherein each of said first and second fusion polypeptides is a fusion polypeptide as defined in claim 4 .

18. A composition comprising:

the dimeric protein of claim 17 ; and

a pharmaceutically acceptable carrier.

19. A dimeric protein comprising a first fusion polypeptide and a second fusion polypeptide, wherein each of said first and second fusion polypeptides is a fusion polypeptide as defined in claim 5 .

20. A composition comprising:

the dimeric protein of claim 19 ; and

a pharmaceutically acceptable carrier.

21. A dimeric protein comprising a first fusion polypeptide and a second fusion polypeptide, wherein each of said first and second fusion polypeptides is a fusion polypeptide as defined in claim 6 .

22. A composition comprising:

the dimeric protein of claim 21 ; and

a pharmaceutically acceptable carrier.

23. A dimeric protein comprising a first fusion polypeptide and a second fusion polypeptide, wherein each of said first and second fusion polypeptides is a fusion polypeptide as defined in claim 7 .

24. A composition comprising:

the dimeric protein of claim 23 ; and

a pharmaceutically acceptable carrier.

25. A dimeric protein comprising a first fusion polypeptide and a second fusion polypeptide, wherein each of said first and second fusion polypeptides is a fusion polypeptide as defined in claim 8 .

26. A composition comprising:

the dimeric protein of claim 25 ; and

a pharmaceutically acceptable carrier.

27. A dimeric protein comprising a first fusion polypeptide and a second fusion polypeptide, wherein each of said first and second fusion polypeptides is a fusion polypeptide as defined in claim 9 .

28. A composition comprising:

the dimeric protein of claim 27 ; and

a pharmaceutically acceptable carrier.

29. A dimeric protein comprising a first fusion polypeptide and a second fusion polypeptide, wherein each of said first and second fusion polypeptides is a fusion polypeptide as defined in claim 10 .

30. A composition comprising:

the dimeric protein of claim 29 ; and

a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2018
From: HAYDEN-LEDBETTER, MARTHA S.; LEDBETTER, JEFFREY A.; MONTES, VINCE
To: THERIPION, INC.
Reel/Frame 045998/0661 →
Continuity (3)
Continuation In Part PCTUS2016050405 · Sep 6, 2016
Provisional Application 62215256 · Sep 8, 2015
Related Publication 20180201664A1 · Jul 19, 2018
References Cited (211)
US 5447851A · Beutler et al. · 1995 [cited by applicant]
US 5795572A · Diegel et al. · 1998 [cited by applicant]
US 6258596B1 · Benoit · 2001 [cited by examiner]
US 8569457B2 · Raines et al. · 2013 [cited by applicant]
US 8937157B2 · Ledbetter et al. · 2015 [cited by applicant]
US 9416188B2 · Chaplin et al. · 2016 [cited by applicant]
US 20030008373A1 · Bartel et al. · 2003 [cited by applicant]
US 20030049694A1 · Wu · 2003 [cited by examiner]
US 20040115183A1 · Rabinkov · 2004 [cited by examiner]
US 20050202532A1 · Bielicki · 2005 [cited by examiner]
US 20060286632A1 · Bielicki · 2006 [cited by examiner]
US 20070111281A1 · Sondermann et al. · 2007 [cited by applicant]
US 20090042787A1 · Metzner et al. · 2009 [cited by applicant]
US 20090318346A1 · Bacus · 2009 [cited by examiner]
US 20100098693A1 · Pardridge · 2010 [cited by examiner]
US 20110178029A1 · Knudsen · 2011 [cited by examiner]
US 20110293557A1 · Prieto · 2011 [cited by examiner]
US 20120121585A1 · Heusser · 2012 [cited by examiner]
US 20140112914A1 · Nezu · 2014 [cited by examiner]
US 20140120091A1 · Ledbetter et al. · 2014 [cited by applicant]
US 20140178379A1 · Ledbetter · 2014 [cited by examiner]
US 20140363428A1 · Igawa · 2014 [cited by examiner]
US 20150353626A1 · Lagerstedt · 2015 [cited by examiner]
US 20160009776A1 · Linden et al. · 2016 [cited by applicant]
US 20160108413A1 · Meulewaeter · 2016 [cited by examiner]
US 20160251638A1 · Posada et al. · 2016 [cited by applicant]
WO 2002038609A2 · 2002 [cited by applicant]
WO 2005018572A2 · 2005 [cited by applicant]
WO 2005047327A2 · 2005 [cited by applicant]
WO 2005063815A2 · 2005 [cited by applicant]
WO WO2006000448A2 · 2006 [cited by examiner]
WO 2013127752A1 · 2013 [cited by applicant]
Rosenblat et al. (2005) Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylchol… [cited by examiner]
Brief for Appellant, In re Theripion, Inc., No. 2022-1346, 2023 WL 5125187 (May 4, 2022). [cited by examiner]
Brief for Director of the United States Patent and Trademark Office, In re Theripion, Inc., No. 2022-1346, 2023 WL 5125187 (Jul. 11, 2022). [cited by examiner]
Reply Brief for Appellant, In re Theripion, Inc., No. 2022-1346, 2023 WL 5125187 (Sep. 14, 2022). [cited by examiner]
Joint Appendix, In re Theripion, Inc., No. 2022-1346, 2023 WL 5125187 (Sep. 21, 2022). [cited by examiner]
Chen et al., “Fusion Protein Linkers: Property, Design and Functionality”, Adv. Drug Delivery Rev. 65:1357-1369, 2013 (Year: 2013). [cited by examiner]
Silacci et al., “Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency”, J. Biol. Chem. 14392-14398, 2014 (Year: 2014). [cited by examiner]
Schmidt, S., “Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges”, pp. 3-24, 2013 (Year: 2013). [cited by examiner]
Medina-Echeverz et al., “Harnessing High Density Lipoproteins to Block Transforming Growth Factor Beta and to Inhibit the Growth of Liver Tumor Metastases”, Cancer Immunol. Immunother. 64:717-725, 2015 (Year: 2015). [cited by examiner]
Communication pursuant to Article 94(3) EPC dated May 30, 2018, issued in corresponding European Patent Application No. 16770394.1, 5 pages. [cited by applicant]
White, C.R., et al., “Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review,” J. Lipid. Res. 55:2007-2021, 2014; published, JLR Papers in Press, Aug. 25, 2014; DOI:10.1194/jlr.R05136… [cited by applicant]
Zamanian-Daryoush, M., “The Cardioprotective Protein Apolipoprotein A1 Promotes Potent Anti-tumorigenic Effects, ”J. Biol. Chem., 288:21237-21252, Jul. 19, 2013; published, JBC Papers In Press, May 17, 2013; DOI:10.1074… [cited by applicant]
Aharoni, A., et al., “Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization,” Proc. Natl. Acad. Sci. USA 101:482-487, Jan. 13, 2004, DOI:10.1073/pnas.2536901100. [cited by applicant]
Bedoya, V.I., et al., “Ribonucleases in HIV Type 1 Inhibition: Effect of Recombinant RNases on Infection of Primary T Cells and Immune Activation-Induced RNase Gene and Protein Expression,” AIDS Research and Human Retro… [cited by applicant]
Berisha, S.Z., et al., “HDL from apoA1 transgenic mice expressing the 4WF isoform is resistant to oxidative loss of function,” J. Lipid Res. 56:653-664, 2015; published, JLR Papers in Press, Jan. 5, 2015; DOI:10.1194/jl… [cited by applicant]
Bernard, M.A., et al., “HIV-Derived ssRNA Binds to TLR8 to Induce Inflammation-Driven Macrophage Foam Cell Formation,” PLoS ONE 9:e104039, Aug. 14, 2014, DOI:10.1371/journal.pone.0104039. [cited by applicant]
Brill, A., et al., “Extrahepatic HDL Receptor SR-BI and apoA-I Protect against Deep Vein Thrombosis in Mice,” Arterioscler. Thromb. Vasc. Biol. Author manuscript; available in PMC Aug. 1, 2013; published in final edited… [cited by applicant]
Ceron, J.J., et al., “Serum paraoxonase 1 (PON1) measurement: an update,” BMC Vet. Res. 10:74, 2014, DOI:10.1186/1746-6148-10-74. [cited by applicant]
Charles-Schoeman, C., et al., “Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis,” Ann. Rheum. Dis. Author manuscript; available in PMC Aug. 27, 2012; published in … [cited by applicant]
Chen, C., et al., “Role of Extracellular RNA and TLR3-Trif Signaling in Myocardial Ischemia-Reperfusion Injury,” J. Am. Heart Assoc. 3:e000683, 2014, DOI:10.1161/JAHA.113.000683. [cited by applicant]
Chen, C., et al., “Protective Effect of RNase on Unilateral Nephrectomy-Induced Postoperative Cognitive Dysfunction In Aged Mice,” PLoS ONE 10:e0134307, Jul. 30, 2015, DOI:10.1371/journal.pone.0134307. [cited by applicant]
Cho, K., and Kim, J., “A reconstituted HDL containing V156K or R173C apoA-I exhibited anti-inflammatory activity in apo-E deficient mice and showed resistance to myeloperoxidase-mediated oxidation,” Exp. Mol. Med. 41:41… [cited by applicant]
Dias, C.G., et al., “Quantification of the arylesterase activity of paraoxonase-1 in human blood,” Anal. Methods 6:289-294, 2014, DOI:10.1039/c3ay41527a. [cited by applicant]
Drew, B.G., et al., “The emerging role of HDL in glucose metabolism,” Nat. Rev. Endocrinol. 8:237-245, 2012; published online Jan. 24, 2012; DOI:10.1038/nrendo.2011.235. [cited by applicant]
Feng, Y., et al., “Cardiac RNA Induces Inflammatory Responses in Cardiomyocytes and Immune Cells via Toll-like Receptor 7 Signaling,” J. Biol. Chem. 290:26688-26698, Oct. 30, 2015; published, JBC Papers in Press, Sep. 1… [cited by applicant]
Goldsmith, M., et al., “Evolved Stereoselective Hydrolases for Broad-Spectrum G-Type Nerve Agent Detoxification,” Chemistry & Biology 19:456-466, Apr. 20, 2012, DOI:10.1016/j.chembiol.2012.01.017. [cited by applicant]
Graverson, J.H., et al., “Trimerization of Apolipoprotein A-I Retards Plasma Clearance and Preserves Antiatherosclerotic Properties,” J. Cardiovasc. Pharmacol. 51:170-177, Feb. 2008. [cited by applicant]
Gugliucci, A., et al., “Enzymatic assessment of paraoxonase 1 activity on HDL subclasses: A practical zymogram method to assess HDL function,” Clin. Chim. Acta 415:162-168, 2013; available online Oct. 30, 2012; DOI:10.1… [cited by applicant]
Hewing, B., et al., “Effects of native and myeloperoxidase-modified apolipoprotein A-I on reverse cholesterol transport and atherosclerosis in mice,” Arterioscler. Thromb. Vasc. Biol. Author manuscript; available in PMC… [cited by applicant]
Ito, A., et al., “Cholesterol Accumulation in CD11c+ Immune Cells Is a Causal and Targetable Factor in Autoimmune Disease,” Immunity 45:1311-1326, Dec. 20, 2016, DOI:10.1016/j.immuni.2016.11.008. [cited by applicant]
Jafri, H., et al., “Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy,” J. Am. Coll. Cardiol. 55:2846-2854, 2010, DOI:10.1016… [cited by applicant]
Kirby, S.D., et al., “Human paraoxonase double mutants hydrolyze V and G class organophosphorus nerve agents,” Chem. Biol. Interact. 203:181-185, 2013; available online Nov. 15, 2012; DOI:10.1016/j.cbi.2012.10.023. [cited by applicant]
Lewis, T.L., et al., “Overexpression of Human Apolipoprotein A-I Preserves Cognitive Function and Attenuates Neuroinflammation and Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer Disease,” J. Biol. Chem. 285:3… [cited by applicant]
Medina-Echeverz, J., et al., “Harnessing High Density Lipoproteins to Block Transforming Growth Factor Beta and to Inhibit the Growth of Liver Tumor Metastases,” PLoS ONE 9:e96799, May 5, 2014, DOI:10.1371/journal.pone.… [cited by applicant]
Moreira, R.S., et al., “Apolipoprotein A-I mimetic peptide 4F attenuates kidney injury, heart injury, and endothelial dysfunction in sepsis,” Am. J. Physiol. Regul. Integr. Comp. Physiol. 307:R514-R524, 2014; first publ… [cited by applicant]
Navab, M., et al., “Oral Administration of an Apo A-I Mimetic Peptide Synthesized From D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol,” Circulation 105:290-292, 2002. [cited by applicant]
Ory, D.S., and Schaffer, J.E., “ApoA-1 in Diabetes: Damaged Goods,” Diabetes 59:2358-2359, Oct. 2010, DOI:10.2337/db10-1040. [cited by applicant]
Otto, T.C., et al., “Dramatic Differences in Organophosphorus Hydrolase Activity between Human and Chimeric Recombinant Mammalian Paraoxonase-1 Enzymes,” Biochemistry 48:10416-10422, 2009, DOI:10.1021/bi901161b. [cited by applicant]
Shao, B., et al., “Myeloperoxidase Impairs ABCA1-dependent Cholesterol Efflux through Methionine Oxidation and Site-specific Tyrosine Chlorination of Apolipoprotein A-I,” J. Biol. Chem. 281:9001-9004, Apr. 7, 2006; publ… [cited by applicant]
Shao, B., et al., “Humans with Atherosclerosis have Impaired ABCA1 Cholesterol Efflux and Enhanced HDL Oxidation by Myeloperoxidase,” Circ. Res. Author manuscript; available in PMC May 23, 2015; published in final edite… [cited by applicant]
Skaggs, B.J., et al. “Dysfunctional, pro-inflammatory HDL directly upregulate monocyte PDGFRβ, chemotaxis and TNFα production,” Clin. Immunol. Author manuscript; available in PMC Oct. 1, 2011; published in final edited … [cited by applicant]
Smith, C.K., et al., “Lupus high-density lipoprotein induces proinflammatory responses in macrophages by binding lectin-like oxidised low-density lipoprotein receptor 1 and failing to promote activating transcription fa… [cited by applicant]
Stevens, R.C., et al., “Engineered recombinant human paraoxonase 1 (rHuPON1) purified from [cited by applicant]
Suzuki, M., et al., “HDL suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide,” Circulation. Author manuscript; available in PMC Nov… [cited by applicant]
Tardy, C., et al., “CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice,” Atherosclerosis 232:110-118, 2014; available o… [cited by applicant]
Yamashita, J., et al., Paraoxonase-1 Suppresses Experimental Colitis via the Inhibition of IFN-gamma Production from CD4 T Cells, J. Immunol. 191:949-960, 2013; prepublished Jun. 14, 2013; DOI:10.4049/jimmunol.1201828. [cited by applicant]
Xianglan, Y., et al., “5A, an Apolipoprotein A-I Mimetic Peptide, Attenuates the Induction of House Dust Mite-induced Asthma,” J. Immunol. Author manuscript; available in PMC Jan. 1, 2012; published in final edited form… [cited by applicant]
Bojic, S., et al., “Low Paraoxonase 1 Activity Predicts Mortality in Surgical Patients with Sepsis,” Disease Markers, vol. 2014, Article ID 427378, pp. 1-8, Feb. 9, 2014, DOI:10.1155/2014/427378. [cited by applicant]
Inal, V., et al., “Paraoxonase 1 Activity and Survival in Sepsis Patients,” Balkan Med. J. 32:183-8, Apr. 2015, DOI:10.5152/balkanmedj.2015.15674. [cited by applicant]
Monigari, N., et al., “Study of Serum HDL Levels in Severe Sepsis Patients in Medical Intensive Care Unit,” International Journal of Scientific and Research Publications, vol. 5, Issue 7, pp. 1-13, Jul. 2015. [cited by applicant]
Morin, E.E., et al., “HDL in sepsis—risk factor and therapeutic approach,” Front. Pharmacol. 6:244, pp. 1-9, Oct. 23, 2015, DOI:10.3389/fphar.2015.00244. [cited by applicant]
Tanaka, S., et al., “Low HDL levels in sepsis versus trauma patients in intensive care unit,” Ann. Intensive Care 7:60, 2017; published online Jun. 6, 2017; DOI:10.1186/s13613-017-0284-3. [cited by applicant]
PCT International Search Report & Written Opinion for PCT/US2016/050405, Jan. 13, 2017, 19 pages. [cited by applicant]
Hiatt, W.R., et al., “Atherosclerotic Peripheral Vascular Disease Symposium II, Nomenclature for Vascular Diseases,” Circulation 118:2826-2829, 2008. [cited by applicant]
Kim, D.S., et al. “Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease,” Pharmacogenomics Author Manuscript; available in PMC Jul. 1, 2014; published in final edited for… [cited by applicant]
Koyama, M., et al., “Interaction between the N- and C-terminal Domain Modulates the Stability and Lipid Binding of Apolipoprotein A-I,” Biochemistry 48:2529-2537, Feb. 24, 2009. [cited by applicant]
Lund-Katz, S., and Phillips, M.C., “High Density Lipoprotein Structure-Function and Role in Reverse Cholesterol Transport,” Subcell Biochem. Author manuscript; available in PMC Nov. 14, 2011; published in final edited f… [cited by applicant]
Mineo, C., and Shaul, P.W., “Novel Biological Functions of High-Density Lipoprotein Cholesterol,” Circulation Research 111:1079-1090, Sep. 28, 2012. [cited by applicant]
Ochoa, M.C., et al., “Liver Gene Transfer of Interleukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy,” PLOS ONE 7:e52370, Dec. 21, 2012, DOI:10.1371/journal.pone.0052370. [cited by applicant]
Phillips, M.C., et al., “New insights into the determination of HDL structure by apolipoproteins,” Journal of Lipid Research 54:2034-2048, 2013; published, JLR Papers in Press, Dec. 10, 2012. [cited by applicant]
Reimers, G.J., et al., “Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I,” Cardiovascular Research 91:37-44, Feb. 24, 2011, DOI:10.1093/cvr/cvr057. [cited by applicant]
Rocco, A.G., et al., “Structural features and dynamics properties of human apolipoprotein A-I in a model of synthetic HDL,” Journal of Molecular Graphics and Modelling 28:305-312, Aug. 27, 2009, DOI:10.1016/j.jmgm.2009.… [cited by applicant]
Sena, A., et al., “Plasma Lipoproteins in Brain Inflammatory and Neurodegenerative Diseases,” Lipoproteins—Role in Health and Diseases, Prof. Gerhard Kostner (Ed.), InTech, 2012, DOI:10.5772/51268. [cited by applicant]
Sorenson, R.C., et al., “Human Serum Paraoxonase/Arylesterase's Retained Hydrophobic N-Terminal Leader Sequence Associates with HDLs by Binding Phospholipids—Apolipoprotein A-I Stabilizes Activity,” Thromb. Vasc. Biol. … [cited by applicant]
Stevens, R.C., et al., “Engineered recombinants human paraoxonase 1 (rHuPON1) purified from [cited by applicant]
Safety Data Sheet, APOA1 (APOAI), Human Prot, Recomb (hIgG1-Fc Tag), Life Technologies, Dec. 4, 2012. [cited by applicant]
Bielicki, J.K., “ABCA1 Agonist Peptides for the Treatment of Disease,” Curr. Opin. Lipidol. Author manuscript; available in PMC Feb. 1, 2017; published in final edited form as Curr. Opin. Lipidol. 27:40-46, Feb. 2016, D… [cited by applicant]
Crosby, N.M., et al., “Anti-CD20 single chain variable antibody fragment-apolipoprotein A-I chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas,” Biochem. Cell Biol. Author … [cited by applicant]
Das, M., et al. “Structural Stability and Local Dynamics in Disease-Causing Mutants of Human Apolipoprotein A-I: What Makes the Protein Amyloidogenic?,” J. Mol. Biol. 2015, DOI:10.1016/j.jmb.2015.10.029. [cited by applicant]
Eren, E., et al., “Functionally Defective High-Density Lipoprotein and Paraoxonase: A Couple for Endothelial Dysfunction in Atherosclerosis,” Cholesterol 2013, Article ID 792090, DOI:10.1155/2013/792090. [cited by applicant]
Fioravanti, J., et al., “The Fusion Protein of IFN-α and Apolipoprotein A-I Crosses the Blood-Brain Barrier by a Saturable Transport Mechanism,” J. Immunol. 188:3988-3992, 2012, prepublished online Mar. 14, 2012, DOI:10… [cited by applicant]
Fisher, S., et al., “Extracellular RNA promotes leukocyte recruitment in the vascular system by mobilising proinflammatory cytokines,” Thromb. Haemost. 108:730-741, 2012, DOI:10.1160/TH12-03-0186. [cited by applicant]
Jun, M., et al., “Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis,” Lancet 375:1875-1884, May 29, 2010, DOI:10.1016/S0140-6736(10)60656-3. [cited by applicant]
Keeney, J.T.R., et al., “Apolipoprotein A-I: Insights from redox proteomics for its role in neurodegeneration,” Proteomics Clin. Appl. 7:109-122, 2013, DOI:10.1002/prca.201200087. [cited by applicant]
Kempen, H.J., et al., “Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol effl ux capacity in cynomolgus monkeys,” J. Lipid Res. 54:2341-2353, 2013, DOI:10.1194/jlr.M033779. [cited by applicant]
Kim, M.J., et al., “Transduced PEP-1-PON1 proteins regulate microglial activation and dopaminergic neuronal death in a Parkinson's disease model,” Biomaterials 64:45-56, 2015, available online Jun. 14, 2015. [cited by applicant]
Kingwell, B.A., and Chapman, M.J., “Future of High-Density Lipoprotein Infusion Therapies—Potential for Clinical Management of Vascular Disease,” Circulation 128:1112-1121, 2013, DOI:10.1161/CIRCULATIONAHA.113.002683. [cited by applicant]
Kingwell, B.A., et al., “HDL-targeted therapies: progress, failures and future,” Nat. Rev. Drug Discov. 13:445-464, Jun. 2014, DOI:10.1038/nrd4279. [cited by applicant]
Koldamova, R.P., et al., “Apolipoprotein A-I Directly Interacts with Amyloid Precursor Protein and Inhibits Aβ Aggregation and Toxicity,” Biochemistry 40:3553-3560, 2001, published on Web Feb. 27, 2001, DOI:10.1021/bi00… [cited by applicant]
Koren-Gluzer, M., et al., “The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates β-cell insulin release,” Atherosclerosis 219:510-518, 2011, available online Aug. 4, 2011, DO… [cited by applicant]
Koutsis, G., et al., “An APOA1 promoter polymorphism is associated with cognitive performance in patients with multiple sclerosis,” Multiple Sclerosis 15:174-179, 2009, DOI:10.1177/1352458508097217. [cited by applicant]
Lehmann, S.M., et al., “Extracellularly Delivered Single-Stranded Viral RNA Causes Neurodegeneration Dependent on TLR7,” J. Immunol. 189:1448-1458, 2012, prepublished online Jun. 27, 2012, DOI:10.4049/jimmunol.1201078. [cited by applicant]
Mackness, B., et al., “Human Paraoxonase-1 Overexpression Inhibits Atherosclerosis in a Mouse Model of Metabolic Syndrome,” Arterioscler. Thromb. Vasc. Biol. 26:1545-1550, 2006, DOI:10.1161/01.ATV.0000222924.62641.aa. [cited by applicant]
Mackness, M., and Mackness, B., “Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles,” Gene 567:12-21, 2015, available online May 9, 2015, DOI:10.1016/j.gen… [cited by applicant]
Menini, T., and Gugliucci, A., “Paraoxonase 1 in neurological disorders,” Redox Report, 19:49-58, 2014, DOI:10.1179/1351000213Y.0000000071. [cited by applicant]
Meyers, L., et al., “A role for Apolipoprotein A-I in the pathogenesis of multiple sclerosis,” J. Neuroimmunol. 277:176-185, 2014, DOI:10.1016/j.neuroim.2014.10.010. [cited by applicant]
Mizuguchi, C., et al., “Amyloidogenic Mutation Promotes Fibril Formation of the N-terminal Apolipoprotein A-I on Lipid Membranes,” J. Biol. Chem. 290:20947-20959, Aug. 21, 2015. [cited by applicant]
Nanjee, M.N., et al., “Effects of Intravenous Infusion of Lipid-Free Apo A-I in Humans,” Arterioscler. Thromb. Vasc. Biol. 16:1203-1214, Sep. 1996, DOI:10.1161/01.ATV.16.9.1203. [cited by applicant]
Newton, D.L., et al., “Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma,” Blood 97:528-535, Jan. 15, 2001, DOI:10.1182/blood.V97.… [cited by applicant]
Nissen, S.E., et al., Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients with Acute Coronary Syndromes—A Randomized Controlled Trial, JAMA 290:2292-2300, Nov. 5, 2003. [cited by applicant]
Obici, L., et al., “Structure, function and amyloidogenic propensity of apolipoprotein A-I,” Amyloid 13:191-205, Dec. 2006, DOI:10.1080/13506120600960288. [cited by applicant]
Paula-Lima, A.C., et al., “Human apolipoprotein A-I binds amyloid-β and prevents Aβ-induced neurotoxicity,” Int. J. Biochem. Cell Biol. 41:1361-1370, 2009, available online Dec. 14, 2008, DOI:10.1016/j.biocel.2008.12.00… [cited by applicant]
Peng, W., et al., “Comparative evaluation of the protective potentials of human paraoxonase 1 and 3 against CCI4-induced liver injury,” Toxicol. Lett. 193:159-166, 2010, available online Jan. 15, 2010, DOI:10.1016/j.tox… [cited by applicant]
Prieto, E.D., et al., “Characterization of a Human Apolipoprotein A-I Construct Expressed in a Bacterial System,” Protein J. 31:681-688, 2012, published online Sep. 18, 2012, DOI:10.1007/s10930-012-9448-z. [cited by applicant]
Reddy, S.T., et al., “Apolipoprotein A-I mimetics,” Curr. Opin. Lipidol. 25:304-308, Aug. 2014, DOI:10.1097/MOL.0000000000000092. [cited by applicant]
Regenass-Lechner, F., et al., “Immunogenicity, Inflammation, and Lipid Accumulation in Cynomolgus Monkeys Infused with a Lipidated Tetranectin-ApoA-I Fusion Protein,” Toxicol. Sci. 150:378-389, 2016; Advance Access Publ… [cited by applicant]
Rosenblat, M., et al., “Injection of paraoxonase 1 (PON1) to mice stimulates their HDL and macrophage antiatherogenicity,” Biofactors 37:462-467, 2011, published online Dec. 8, 2011, DOI:10.1002/biof.188. [cited by applicant]
Ryan, R., et al., “Optimized bacterial expression of human apolipoprotein A-I,” Protein Expr. Purif. 27:98-103, 2003. [cited by applicant]
Simsekyilmaz, S., et al., “Role of Extracellular RNA in Atherosclerotic Plaque Formation in Mice,” Circulation 129:598-606, 2014, DOI:10.1161/CIRCULATIONAHA.113.002562. [cited by applicant]
Su, F., et al., “Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer,” Proc. Natl. Acad. Sci. USA 107:19997-20002, Nov. 16, 2010. [cited by applicant]
Sun, X., et al., “Increased Ribonuclease Expression Reduces Inflammation and Prolongs Survival in TLR7 Transgenic Mice,” J. Immunol. 190:2536-2543, 2013, prepublished online Feb. 4, 2013, DOI:10.4049/jimmunol. 1202689. [cited by applicant]
Walberer, M., et al., “RNase therapy assessed by magnetic resonance imaging reduces cerebral edema and infarction size in acute stroke,” Curr. Neurovasc. Res. 6:12-19, 2009, PMID 19355922, Abstract. [cited by applicant]
Segrest, J.P., et al., “Structure and function of apolipoprotein A-I and high density lipoprotein,” Curr. Opin. Lipidol. 11:105-115, 2000. [cited by applicant]
Lu, S., et al., “An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice,” J. Lipid Res. 53:643-652, 2012; published, JLR Papers in Press, Jan. 27, 2012, DOI:10.1194/jlr.M0… [cited by applicant]
Boado, R.J., et al., “IgG-Paraoxonase-1 Fusion Protein for Targeted Drug Delivery Across the Human Blood-Brain Barrier,” Mol. Pharm. Author manuscript; available in PMC Nov. 9, 2009; published in final edited form as Mo… [cited by applicant]
Boado, R.J., et al., “CHO Cell Expression, Long-Term Stability, and Primate Pharmacokinetics and Brain Uptake of an IgG-Paraoxonase-1 Fusion Protein,” Biotechnology and Bioengineering 108:186-196, Jan. 1, 2011; publishe… [cited by applicant]
Linderholm, A.L., and Chamow, S.M., “Immunoglobulin Fc-Fusion Proteins Part 1: Their Design and Manufacture,” BioProcess International 12:30-35, Oct. 2014. [cited by applicant]
Cabrera-Fuentes et al., “RNase1 as a potential mediator of remote ischaemic preconditioning for cardioprotection,” Eur. J. Cardiothorac. Surg. 48:732-737, Jan. 2015. [cited by applicant]
Aicher, A., et al., “Characterization of Human Inducible Costimulator Ligand Expression and Function,” J. Immunol. 164:4689-4696, 2000, DOI:10.4049/jimmunol. 164.9.4689. [cited by applicant]
Arrigoni, C., et al., “The voltage-sensing domain of a phosphatase gates the pore of a potassium channel,” J. Gen. Physiol. 141:389-395, 2013, DOI:10.1085/jgp.201210940. [cited by applicant]
Belsare, K.D., et al., “P-Link: A method for generating multicomponent cytochrome P450 fusions with variable linker length,” BioTechniques 57:13-20, Jul. 2014, DOI:10.2144/000114187. [cited by applicant]
Chen, X., “Fusion Protein Linkers: Property, Design and Functionality,” Adv. Drug Deliv. Rev. Author manuscript; available in PMC Oct. 15, 2014; published in final edited form as Adv. Drug Deliv. Rev. 65:1357-1369, Oct.… [cited by applicant]
Connelly, R.S., et al., “Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes,” Int. Immunol. 10:1863-1872, 1998. [cited by applicant]
Contarino, M., et al., “Chimeric Cyanovirin-MPER Recombinantly Engineered Proteins Cause Cell-Free Virolysis of HIV-1,” Antimicrob. Agents Chemother. 57:4743-4750, Oct. 2013, published ahead of print Jul. 15, 2013, DOI:… [cited by applicant]
Evers, T.H., et al., “Quantitative Understanding of the Energy Transfer between Fluorescent Proteins Connected via Flexible Peptide Linkers,” Biochemistry 45:13183-13192, 2006, published on Web Oct. 12, 2006, DOI:10.102… [cited by applicant]
Fan, G., et al., “Bispecific antibodies and their applications,” J. Hematol. Oncol. 8:130, 2015, DOI:10.1186/s13045-015-0227-0. [cited by applicant]
Gilliland, L.K., et al., “Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments,” Tissue Antigens 47:1-20, 1996. [cited by applicant]
Guo, H., et al., “Effect of flexible linker length on the activity of fusion protein 4-coumaroyl-CoA ligase::stilbene synthase,” Mol. BioSyst. 13:598-606, 2017, DOI:10.1039/c6mb00563b. [cited by applicant]
Hayden, M.S., et al., “Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system,” Ther. Immunol. 1:3-15, 1994. [cited by applicant]
Hayden, M.S., et al., “Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen,” Tissue Antigens 48:242-254, 1996. [cited by applicant]
Hayden-Ledbetter, M.S., et al., “CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells,” Clin. Cancer Res. 15:2739-2746, 2009. [cited by applicant]
Hellstrom, I., et al., “The HE4 (WFDC2) Protein Is a Biomarker for Ovarian Carcinoma,” Cancer Res. 63:3695-3700, Jul. 1, 2003. [cited by applicant]
Hudson, P.J., and Kortt, A.A., “High avidity scFv multimers; diabodies and triabodies,” J. Immunol. Methods 231:177-189, 1999. [cited by applicant]
Jung, A., et al., “Linker length and fusion site composition improve the optical signal of genetically encoded fluorescent voltage sensors,” Neurophotonics 2:021012, Apr.-Jun. 2015, DOI:10.1117/1.NPh.2.2.021012. [cited by applicant]
Klement, M., et al., “Effect of linker flexibility and length on the functionality of a cytotoxicengineered antibody fragment,” J. Biotechnol. 199:90-97, 2015, DOI:10.1016/j.jbiotec.2015.02.008. [cited by applicant]
Kong, Y., et al., “Linker engineering for fusion protein construction: Improvement and characterization of a GLP-1 fusion protein,” Enzyme Microb. Technol. 82:105-109, 2016, DOI:10.1016/j.enzmictec.2015.09.001. [cited by applicant]
Law, C., et al., “Linker engineering for fusion protein construction: Improvement and characterization of a GLP-1 fusion protein,” Int. Immunol. 14:389-400, Apr. 2002. [cited by applicant]
Linsley, P.S., et al., “CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7,” J. Exp. Med. 174:561-569, Sep. 1991. [cited by applicant]
Linsley, P.S., et al., “Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation,” J. Exp. Med. 173:721-730, Mar. 1991. [cited by applicant]
Mack, E.T., “Dependence of Avidity on Linker Length for a Bivalent Ligand-Bivalent Receptor Model System,” J. Am. Chem. Soc. Author manuscript; available in PMC Jan. 11, 2013; published in final edited form as J. Am. Ch… [cited by applicant]
Robinson-Mosher, A., et al., “Designing Cell-Targeted Therapeutic Proteins Reveals the Interplay between Domain Connectivity and Cell Binding,” Biophysical J. 107:2456-2466, Nov. 2014, DOI:10.1016/j.bpj.2014.10.007. [cited by applicant]
Scholler, N., et al., “Cutting Edge: CD83 Regulates the Development of Cellular Immunity,” J. Immunol. 168:2599-2602, 2002. [cited by applicant]
Shan, D., et al., “Characterization of scFv-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths,” J. Immunol. 162:6589-6595, 1999. [cited by applicant]
Shastry, S., and Hancock, W.O., “Neck Linker Length Determines the Degree of Processivity in Kinesin-1 and Kinesin-2 Motors,” Curr. Biol. Author manuscript; available in PMC May 25, 2011; published in final edited form … [cited by applicant]
Silacci, M., et al., “Linker Length Matters, Fynomer-Fc Fusion with an Optimized Linker Displaying Picomolar IL-17A Inhibition Potency,” J. Biol. Chem. 289:14392-14398, May 16, 2014; published, JBC Papers in Press, Apr.… [cited by applicant]
Wittenberg, G., et al., “Accelerated electron transport from photosystem I to redox partners by covalently linked ferredoxin,” Phys. Chem. Chem. Phys. 15:19608-19614, 2013, DOI:10.1039/c3cp53264j. [cited by applicant]
Human ApoAI Protein (Fc Tag), Catalog No. 10686-H02H, Sino Biological, product information downloaded from manufacturer's website on Apr. 4, 2019. [cited by applicant]
Recombinant Human APOA1, Fc tagged, APOA1-33H Human, Creative BioMart, product information downloaded from manufacturer's website on Apr. 4, 2019. [cited by applicant]
Aruffo, A., et al., “CD44 Is the Principal Cell Surface Receptor for Hyaluronate,” Cell 61:1303-1313, Jun. 29, 1990. [cited by applicant]
Bitonti, A.J., et al., “Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway,” Proc. Natl. Acad. Sci. USA 101:9763-9768, Jun. 29, 2004, DOI:10.1073/… [cited by applicant]
Byrn, R.A., et al., “Biological properties of a CD4 immunoadhesin,” Nature 344:667-670, Apr. 12, 1990. [cited by applicant]
Capon, D.J., et al., “Designing CD4 immunoadhesins for AIDS therapy,” Nature 337:525-531, Feb. 9, 1989. [cited by applicant]
Chalupny, N.J., et al., “T-cell activation molecule 4-1BB binds to extracellular matrix proteins,” Proc. Natl. Acad. Sci. USA 89:10360-10364, Nov. 1992. [cited by applicant]
Chapoval, A.I., et al., “Immunoglobulin Fusion Proteins as a Tool for Evaluation of T-Cell Costimulatory Molecules,” in Methods in Molecular Medicine, vol. 45: Hepatocellular Carcinoma Methods and Protocols, 247-255 (N.… [cited by applicant]
Chapoval, A.I., et al., “B7-H3:A costimulatory molecule for T cell activation and IFN-γ production,” Nat. Immunol. 2:269-274, Mar. 2001. [cited by applicant]
Cox, G.N., et al., “Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein,” Exp. Hematol. 32:441-449, 2004, DOI:10.1016/j.exphem.2004.… [cited by applicant]
Dong, H., et al., “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,” Nat. Med. 5:1365-1369, Dec. 1999. [cited by applicant]
Godfrey, W.R., et al., “Identification of a Human OX-40 Ligand, a Costimulator of CD4+ T Cells with Homology to Tumor Necrosis Factor,” J. Exp. Med. 180:757-762, Aug. 1994. [cited by applicant]
Hollenbaugh, D., et al., “The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity,” EMBO J. 11:4313-432… [cited by applicant]
Hollenbaugh, D., et al., “Cleavable CD40Ig fusion proteins and the binding to sgp39,” J. Immunol. Methods 188:1-7, 1995. [cited by applicant]
Hu, P., et al., “Construction and Preclinical Characterization of Fc-mGITRL for the Immunotherapy of Cancer,” Clin. Cancer Res. 14:579-588, Jan. 15, 2008. [cited by applicant]
Kelm, S., et al., “Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily,” Curr. Biol. 4:965-972, 1994. [cited by applicant]
Kelm, S., et al., “The Ligand-binding Domain of CD22 Is Needed for Inhibition of the B Cell Receptor Signal, as Demonstrated by a Novel Human CD22-specific Inhibitor Compound,” J. Exp. Med. 195:1207-1213, May 6, 2002, D… [cited by applicant]
Lane, P., et al., “Expression and functional properties of mouse B7/BB1 using a fusion protein between mouse CTLA4 and human γ1,” Immunology 80:56-61, 1993. [cited by applicant]
Mahlangu, J., et al., “Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A,” Blood 123:317-325, Jan. 16, 2014. [cited by applicant]
Mancuso, M.E., and Mannucci, P.M., “Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias,” Drug Des. Dev. Ther. 8:365-371, Mar. 28, 2014, DOI:10.2147/DDDT.S47312. [cited by applicant]
Miller, G.T., et al., “Specific Interaction of Lymphocyte Function-associated Antigen 3 with CD2 Can Inhibit T Cell Responses,” J. Exp. Med. 178:211-222, Jul. 1993, DOI:10.1084/jem.178.1.211. [cited by applicant]
Murphy, K.A., et al., “An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas,” Clin. Cancer Res. 18:4657-4668, 2012; Published… [cited by applicant]
Noelle, R.J., et al., “A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells,” Proc. Natl. Acad. Sci. USA 89:6550-6554, Jul. 1992. [cited by applicant]
Peach, R.J., et al., “Complementarity Determining Region 1 (CDR1)- and CDR3-analogous Regions in CTLA-4 and CD28 Determine the Binding to B7-1,” J. Exp. Med. 180:2049-2058, Dec. 1994, DOI:10.1084/jem.180.6.2049. [cited by applicant]
Peach, R.J., et al., “Both Extracellular Immunoglobin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28,” J. Biol. Chem. 270:21181-21187, Sep. 8, 1995. [cited by applicant]
Peters, R.T., et al., “Prolonged activity of factor IX as a monomeric Fc fusion protein,” Blood 115:2057-2064, 2010, DOI:10.1182/blood-2009-08-239665. [cited by applicant]
Pollock, K.E., et al., “Inducible T Cell Antigen 4-1 BB,” J. Immunol. 150:771-781, Feb. 1, 1993. [cited by applicant]
Salas, J., et al., “Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion,” Thromb. Res. 135:970-976, 2015; available online Jan. 3, 2015. [cited by applicant]
Sgroi, D., et al., “Regulation of CD45 engagement by the B-cell receptor CD22,” Proc. Natl. Acad. Sci. USA 92:4026-4030, Apr. 1995. [cited by applicant]
Traunecker, A., et al., “Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules,” Nature 339:68-70, May 4, 1989. [cited by applicant]
Wang, S., et al., “Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS,” Blood 96:2808-2813, Oct. 15, 2000. [cited by applicant]
Zhang, N., et al., “Targeted and Untargeted CD137L Fusion Proteins for the Immunotherapy of Experimental Solid Tumors,” Clin. Cancer Res. 13:2758-2767, May 1, 2007. [cited by applicant]
Dwyer, M.A., et al., “Expression and Characterization of a DNase I-Fc Fusion Enzyme,” J. Biol. Chem. 274:9738-9743, Apr. 2, 1999. [cited by applicant]
Bagley, R.G., et al., “sFLT01: A Novel Fusion Protein with Antiangiogenic Activity,” Mol. Cancer Ther. 10:404-415, Mar. 2011; published OnlineFirst Jan. 20, 2011; DOI:10.1158/1535-7163.MCT-10-0813. [cited by applicant]
De Beer, M.C., et al., “Apolipoprotein A-I conformation markedly influences HDL interaction with scavenger receptor BI,” J. Lipid. Res. 42:309-313, 2001. [cited by applicant]
Jazayeri, J.A., et al., “Generation of mutant leukaemia inhibitory factor (LIF)-IgG heavy chain fusion proteins as bivalent antagonists of Lif,” J. Immunol. Methods 323:1-10, 2007; available online Mar. 28, 2007; DOI:10… [cited by applicant]
Jones, T.D., et al., “The Development of a Modified Human IFN-a2b Linked to the Fc Portion of Human IgG1 as a Novel Potential Therapeutic for the Treatment of Hepatitis C Virus Infection,” J. Interferon Cytokine Res. 24… [cited by applicant]
Lewis, V.A., et al., “Human Nerve Growth Factor Receptor and Cytosine Deaminase Fusion Genes,” Hum. Gene Ther. 14:1009-1016, Jul. 1, 2003. [cited by applicant]
Mezo, A.R., et al., “Atrial Natriuretic Peptide-Fc, ANP-Fc, Fusion Proteins: Semisynthesis, In Vitro Activity and Pharmacokinetics in Rats,” Bioconjugate Chem. 23:518-526, Jan. 22, 2012, DOI:10.1021/bc200592c. [cited by applicant]
Spahr, C., et al., “Recombinant human lecithin-cholesterol acyltransferase Fc fusion: Analysis of N- and O-linked glycans and identification and elimination of a xylose-based O-linked tetrasaccharide core in the linker … [cited by applicant]
Hu, S., et al., “Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-CH3) Which Exhibits Rapid, High-Level Targeting of Xenografts,” Cancer Res. 56:3055-3061, Jul. 1, 1996. [cited by applicant]
Loffler, A., et al., “A recombinant bispecific single-chain antibody, CD19xCD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes,” Blood 95:2098-2013, Mar. 15, 2000. [cited by applicant]
Mack, M., et al., “A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity,” Proc. Natl. Acad. Sci. USA 92:7021-7025, Jul. 1995. [cited by applicant]